Pneumococcal vaccine from GSK’s latest
coolhealthtips.com
GlaxoSmithKline (GSK) has recently launched the latest generation for the pneumococcal vaccine with a more affordable price. The vaccine, given the generic name PHiD-CV (Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine) is to protect children from diseases caused by invasive pneumococcal infections dangerous (Invasive Pneumococcal Diseases-IPD), i.e., meningitis, pneumonia and bacteremia, as well as disease non-invasive such as middle ear infection (otitis media).
The presence of IPD vaccine was greeted positively by health professionals. It is desirable in the presence of this vaccine can help reduce ANGA deaths in children under five years because of pneumonia caused by Streptococcus pneumoniae.
IPD GSK vaccine production is indicated for children between ages 2 months to 2 years is the latest generation of vaccine after a similar vaccine PCV7 generation that circulate in the community.
GSK’s vaccine IPD is to protect children from pneumococcal infections such as meningitis (inflammation of the lining of the brain) and pneumonia (inflammation of the lungs) which is the largest cause of death in children under the age of five years and also against acute middle ear infection.
This vaccine provides broader protection because it consists of 10 serotype (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) and is the first vaccine and the only one that uses a component of the bacterium Streptococcus pneumoniae and non- type able Haemophilus influenzae (NTHi).
IPD GSK’s vaccine has been launched in over 60 countries, and has received prequalification for use globally by the WHO in November 2009 which means it will extend the vaccine for global use, particularly for developing countries.
